{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:57:26Z","timestamp":1783544246190,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R34 MH101267"],"award-info":[{"award-number":["R34 MH101267"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["K23 MH120324"],"award-info":[{"award-number":["K23 MH120324"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Despite advances in the treatment of bipolar disorder (BD), most patients do not achieve complete inter-episode recovery and functional disability is common. During periods of relative remission, many patients continue to experience neurocognitive dysfunction, reduced daytime activity levels, and sleep disturbances. This 8-week, randomized, placebo-controlled pilot study evaluated the feasibility, safety and preliminary efficacy of the wake-promoting drug, modafinil (Provigil<jats:sup>\u00ae<\/jats:sup>), on neurocognitive functioning, daytime sleepiness, and sleep quality in affectively-stable BD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twelve individuals with affectively-stable BD were recruited and randomized to a flexible dose of modafinil (100 to 200\u2009mg\/day) or placebo, adjunctive to a therapeutic dose of a mood stabilizer. Weekly in-person visits tracked sleep quality and daytime sleepiness as well as side effects and mood symptoms. Neurocognitive functioning was assessed at baseline, week 4, and week 8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No serious adverse events were reported. Newly emergent side effects in the modafinil group included heart palpitations, itching, fatigue, and decreased energy. Two patients discontinued modafinil owing to side effects and one of these patients withdrew from the study. One patient discontinued placebo and was withdrawn from the study. Preliminary evaluations of clinical efficacy showed a marginally significant interaction between treatment group and time in two cognitive domains (speed of processing and verbal learning), indicating greater improvement in the modafinil group versus placebo. Additionally, there was a marginally significant effect of treatment group on daytime sleepiness, suggesting lower daytime sleepiness in the modafinil group versus placebo. Counterintuitively, we found a significant treatment group by time interaction effect on sleep quality, suggesting greater improvement in sleep quality in the placebo group versus the modafinil group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Results suggest that modafinil is a relatively safe medication for affectively-stable BD patients when given with adjunctive mood stabilizers. Results are suggestive of cognitive benefit and improved daytime sleepiness, but worse sleep quality in those patients prescribed modafinil. A fully powered clinical trial is warranted with specific attention to the characteristics of patients who are most likely to benefit from treatment with modafinil and other methodological lessons learned from this pilot.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, identifier NCT01965925.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1246149","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:45:11Z","timestamp":1693813511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Modafinil\u2019s effects on cognition and sleep quality in affectively-stable patients with bipolar disorder: a pilot study"],"prefix":"10.3389","volume":"14","author":[{"given":"Jessica M.","family":"Lipschitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Perez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Locascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea K.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Shanahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Burdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4088\/JCP.v63n0910","article-title":"Subsyndromal depression is associated with functional impairment in patients with bipolar disorder","volume":"63","author":"Altshuler","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1176\/appi.ajp.160.12.2099","article-title":"The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence","volume":"160","author":"Tohen","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jad.2008.07.006","article-title":"The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD","volume":"114","author":"Marangell","year":"2009","journal-title":"J Affect Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1399-5618.2004.00111.x","article-title":"Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome","volume":"6","author":"Martinez-Aran","year":"2004","journal-title":"Bipolar Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1176\/appi.ajp.162.1.50","article-title":"Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems","volume":"162","author":"Harvey","year":"2005","journal-title":"Am J Psychiatry"},{"key":"ref7","volume-title":"Cognitive dysfunction in bipolar disorder: a guide for clinicians","author":"Goldberg","year":"2008"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11920-009-0074-1","article-title":"Melatonin, circadian rhythms, and the clock genes in bipolar disorder","volume":"11","author":"Dallaspezia","year":"2009","journal-title":"Curr Psychiatry Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"12824","DOI":"10.1523\/JNEUROSCI.3353-09.2009","article-title":"Cycling behavior and memory formation","volume":"29","author":"Gerstner","year":"2009","journal-title":"J Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpsychires.2009.08.003","article-title":"Functional impact of biological rhythm disturbance in bipolar disorder","volume":"44","author":"Giglio","year":"2010","journal-title":"J Psychiatr Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.brainresrev.2009.09.005","article-title":"Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges","volume":"62","author":"Benca","year":"2009","journal-title":"Brain Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2015.08.009","article-title":"The relationship between sleep quality and neurocognition in bipolar disorder","volume":"187","author":"Russo","year":"2015","journal-title":"J Affect Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/DDDT.S2377","article-title":"Modafinil in the treatment of excessive sleepiness","volume":"2","author":"Schwartz","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1034\/j.1399-5618.2001.30403.x","article-title":"Substance abuse in bipolar disorder","volume":"3","author":"Cassidy","year":"2001","journal-title":"Bipolar Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bdi.12859","article-title":"Efficacy and tolerability of adjunctive modafinil\/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials","volume":"22","author":"Nunez","year":"2020","journal-title":"Bipolar Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/sj.npp.1301534","article-title":"Modafinil: a review of neurochemical actions and effects on cognition","volume":"33","author":"Minzenberg","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bpsc.2016.11.009","article-title":"Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study","volume":"2","author":"Kaser","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0006-3223(94)91193-2","article-title":"The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity","volume":"36","author":"Altman","year":"1994","journal-title":"Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1037\/0022-006X.47.2.343","article-title":"Assessment of suicidal ideation: the scale for suicidal ideation","volume":"47","author":"Beck","year":"1979","journal-title":"J Consult Clin Psychol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref22","volume-title":"Structured Clinical Interview for DSM-IV (SCID)","author":"First","year":"1997"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr Bull"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/npp.2011.36","article-title":"The MATRICS Consensus Cognitive Battery in patients with bipolar I disorder","volume":"36","author":"Burdick","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.07.011","article-title":"Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain","volume":"64","author":"Scoriels","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00213-011-2472-4","article-title":"Effects of modafinil on cognitive functions in first episode psychosis","volume":"220","author":"Scoriels","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1176\/appi.ajp.2007.06060981","article-title":"A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression","volume":"164","author":"Frye","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.4088\/JCP.v67n1122a","article-title":"Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil","volume":"67","author":"Wolf","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/01.jcp.0000185346.77966.a4","article-title":"Modafinil-induced irritability and aggression? A report of 2 bipolar patients","volume":"25","author":"Ranjan","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/bdi.12612","article-title":"Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis","volume":"20","author":"Fornaro","year":"2018","journal-title":"Bipolar Disord"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1246149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:45:16Z","timestamp":1693813516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1246149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":35,"alternative-id":["10.3389\/fpsyt.2023.1246149"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1246149","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"article-number":"1246149"}}